The drugs used were (+)-methamphetamine hydrochloride (Sigma, St Louis, MO) and SCH23390 hydrochloride (TOCRIS bioscience, Ellisville, MO). All drugs were diluted with 0.9% saline. We have selected the METH dose based on previous studies showing that repeated non-contingent 7 days METH treatment (1 mg/kg) was able to induce cognitive impairments associated with deficits of the ERK1/2 pathway in the mPFC (González et al., 2014 (link); also see Kamei et al., 2006 (link)). In the present study, METH was administered subcutaneously (s.c.) once a day for 7 days (1 mg/Kg, calculated as free base). To test D1/5 receptors effect, animals received intraperitoneal (i.p.) injections of the D1 receptor antagonist, SCH 23390 (0.5 and 0.05 mg/kg, for 7 days), 30 min before each injection of saline or METH. Vehicle groups received the same volume of sterile saline solution. Mice were killed 4 days after the last METH/saline injection.